Barrington analyst Michael Petusky lowered the firm’s price target on Anika Therapeutics (ANIK) to $15 from $19 and keeps an Outperform rating on the shares, citing “incrementally negative Hyalofast news” for the firm’s lowered target. However, shares are “meaningfully undervalued and trading near max skepticism after yesterday’s 27% decline,” the analyst argues.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIK: